Gold Colloid, Co., a new company focused on the development of point-of-care rapid immunodiagnostic lateral flow tests, today announced its launch
San Diego, CA – August 24, 2023 – Gold Colloid, Co., a new company focused on the development of point-of-care rapid immunodiagnostic lateral flow tests, today announced its launch. The company is led by a team of experienced scientists and entrepreneurs with a proven track record in the development and commercialization of diagnostic tests.
Point-of-care rapid immunodiagnostic lateral flow tests are used to detect the presence of a disease or infection in a patient’s sample. They are typically simple to use and can provide results in minutes, making them ideal for use in a variety of settings, including healthcare facilities, schools, and workplaces.
Gold Colloid, Co. is developing a portfolio of point-of-care rapid immunodiagnostic lateral flow test raw materials and services. The company’s tests are designed to be highly accurate and reliable, and they are expected to be more affordable than traditional diagnostic tests.
“We are excited to launch Gold Colloid, Co. and to bring our innovative point-of-care rapid immunodiagnostic lateral flow tests to market,” said Daniel Levenson, CEO of Gold Colloid, Co. “We believe that our tests have the potential to revolutionize the way that diseases are diagnosed and treated.”
Gold Colloid Co. is currently seeking funding to support the development and commercialization of its products and services. The company is also looking for partners to collaborate on the development of new tests and technologies.